(Tempo-3) Flexible-Dose, Adjunctive Therapy Trial in Adults with Parkinson's Disease with Motor Fluctuations

Clinical Trial Title

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for PD in Levodopa-Treated Adults With Motor Fluctuations

National Clinical Trial Number:


Contact Information

Andrea Hernandez, BS

Clinical Trial Protocol Description:

The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's disease (PD) who are experiencing motor fluctuations.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have a modified Hoehn and Yahr stage 2, 2.5, or 3 in the "on" state.
  • Have a good response to levodopa (L-Dopa) in the judgment of the investigator.
  • Return a completed self-reported home diary for motor function status (Hauser diary) during the screening period (after diary training and concordance testing has occurred), with recordings for 2 consecutive days (ie, 2 consecutive 24-hour periods) showing at least 2 and half hours of "off" time on each of the 2 days.
  • Are on a stable dose of L-Dopa for at least 4 weeks prior to screening and are taking a minimum total daily dose of 400 milligram (mg) divided in at least 4 doses per day of standard carbidopa/levodopa or divided in at least 3 doses per day of extended-release carbidopa/levodopa capsules. 

You will be excluded from the study if any of the following criteria apply to you:

  • Have a history or clinical features consistent with essential tremor, atypical or secondary parkinsonian syndrome (including, but not limited to, progressive supranuclear palsy, multiple system atrophy, cortico-basal degeneration, or drug-induced or poststroke parkinsonism).
  • Have a history of nonresponse or insufficient response to L-Dopa at therapeutic dosages.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Christopher Goetz, MD

Contact Information

Andrea Hernandez, BS

Clinical Trial Location

RUSH University Medical Center
RUSH Copley Medical Center


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

RUSH Copley Medical Center

2000 Ogden Ave
Aurora, IL 60504

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more